Dr George Matcham is a cell therapy expert with over 30 years of experience at Celgene Corporation, where he championed the introduction of cellular immunotherapy and led the establishment of cell therapy & biologics technical development.
Dr Matcham joined Celgene in 1988 when the company was a 30-person startup, and after 3 decades of successful leadership he retired in 2018 with the company shortly being acquired for $74B by Bristol-Myers Squibb (BMS). Dr Matcham was vital to the growth of cell therapy at Celgene. He held several leadership positions including as chief operations officer of Celgene Cellular Therapeutics and senior vice president of CAR T CMC Development where he oversaw clinical supply.
Dr Matcham holds a PhD in Biochemistry from Cardiff University.
